Association of Age With SARS-CoV-2 Antibody Response

He S Yang1,2, Victoria Costa1,2, Sabrina E Racine-Brzostek1,2

  • 1Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.

JAMA Network Open
|March 22, 2021
PubMed

Insights

Children and adolescents show distinct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses compared to adults. This suggests age-specific strategies for SARS-CoV-2 management and vaccine development are needed.

Area of Science:

  • Immunology
  • Virology
  • Pediatrics

Background:

  • Children infected with SARS-CoV-2 typically experience milder symptoms than adults.
  • The differences in immune responses to SARS-CoV-2 between children, adolescents, and adults remain unclear.

Purpose of the Study:

  • To investigate how age influences the quantity and quality of SARS-CoV-2 antibody responses.
  • To compare SARS-CoV-2 antibody profiles across different age groups, including children, adolescents, and young adults.

Main Methods:

  • A cross-sectional study analyzed 31,426 SARS-CoV-2 antibody test results from pediatric and adult patients in New York City.
  • Semiquantitative immunoglobulin (Ig) G levels were compared between pediatric and adult patient groups.
  • Detailed antibody profiles (IgG, total antibody [TAb], surrogate neutralizing antibody [SNAb] activity, and avidity) were analyzed in a subset of patients aged 1 to 24 years.

Main Results:

  • Seroprevalence of SARS-CoV-2 antibodies was similar between pediatric and adult populations.
  • SARS-CoV-2 IgG levels showed a negative correlation with age in children and a positive correlation in adults.
  • Children exhibited significantly higher IgG, TAb levels, and SNAb activity compared to adolescents and young adults. Adolescents also showed higher levels than young adults.

Conclusions:

  • SARS-CoV-2-specific antibody response profiles differ significantly across age groups.
  • Findings suggest the need for age-tailored strategies for disease screening, management, and vaccine development.
Abstract